Tarsus Pharmaceuticals reported total assets of $505.50M and total liabilities of $401.47M for the quarter ended Sep 2026, down 5.4% year over year. This balance sheet covers 29 quarters of results from Sep 2019 through Sep 2026, standardized by Business Quant from the company’s SEC filings.
| Balance SheetBalance Sheet | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 | Sep2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||||||||||||
| Current Assets | |||||||||||||||||||||||||||||
| Cash & EquivalentsCash & Equiv. | 171.33M | 175.01M | 245.40M | 71.66M | 224.95M | ||||||||||||||||||||||||
| Short-term InvestmentsInvestments (Current) | 0.48M | 0.29M | 57.08M | 145.37M | 135.22M | 71.46M | 20.21M | 2.50M | 104.82M | 142.49M | 140.74M | 196.56M | 232.13M | 284.50M | 289.11M | 233.63M | 286.54M | 245.10M | 173.08M | ||||||||||
| Cash & Current Investments | 171.82M | 175.30M | 245.40M | 57.08M | 217.03M | 135.22M | 71.46M | 20.21M | 227.44M | 104.82M | 142.49M | 140.74M | 196.56M | 232.13M | 284.50M | 289.11M | 233.63M | 286.54M | 245.10M | 173.08M | |||||||||
| Receivables - NetNet Receivables | 0.02M | 0.02M | 0.02M | 2.50M | 5.36M | 16.62M | 29.89M | 29.53M | 29.16M | 46.76M | 62.43M | 58.33M | 72.62M | 85.06M | 100.34M | 96.03M | 100.44M | ||||||||||||
| Receivables - OtherOther Receivables | 0.09M | 0.31M | 0.60M | 4.00M | 3.58M | 0.42M | 0.25M | 1.01M | 1.09M | 1.48M | 1.31M | 1.15M | 1.30M | 1.73M | 1.91M | 1.72M | 2.05M | 16.86M | 2.28M | 1.67M | |||||||||
| Receivables | 0.09M | 0.32M | 0.62M | 4.01M | 3.58M | 2.92M | 6.37M | 17.71M | 31.36M | 30.84M | 30.30M | 48.06M | 64.15M | 60.24M | 74.34M | 87.11M | 117.21M | 98.31M | 102.11M | ||||||||||
| Raw Materials | 2.53M | 2.53M | |||||||||||||||||||||||||||
| Work In Process | 0.39M | 0.68M | 1.20M | 1.59M | 0.61M | 0.76M | 1.58M | 1.00M | 1.41M | 1.63M | 1.36M | 3.06M | |||||||||||||||||
| Finished Goods | 0.18M | 0.83M | 1.00M | 1.25M | 2.01M | 1.94M | 2.29M | 2.84M | 2.96M | 2.94M | 3.02M | 2.10M | |||||||||||||||||
| Inventory | 0.02M | 3.11M | 4.04M | 2.20M | 2.85M | 2.62M | 2.71M | 3.87M | 3.84M | 4.37M | 4.57M | 4.38M | 5.16M | ||||||||||||||||
| Prepaid Assets | 4.05M | 3.13M | 4.30M | 3.49M | 4.77M | 4.51M | 5.00M | 6.01M | 7.87M | 6.80M | 5.97M | 7.02M | 14.65M | 6.00M | 29.17M | 21.70M | 13.47M | 26.72M | 9.61M | 28.54M | |||||||||
| Current Assets | 175.95M | 178.76M | 250.28M | 234.08M | 225.38M | 208.65M | 183.48M | 259.28M | 256.13M | 340.72M | 362.59M | 357.12M | 356.71M | 480.77M | 474.43M | 501.70M | 522.78M | 537.23M | 561.99M | 445.42M | |||||||||
| Non-Current Assets | |||||||||||||||||||||||||||||
| Property, Plant & Equipment (Net)PP&E (Net) | 0.76M | 0.92M | 0.96M | 0.95M | 0.96M | 1.19M | 1.54M | 1.61M | 1.47M | 1.34M | 2.24M | 2.39M | 2.31M | 2.79M | 3.18M | 5.75M | 11.67M | 17.67M | 20.49M | 20.72M | |||||||||
| Long-Term Investments | 0.17M | 0.16M | 0.37M | 0.31M | 0.32M | 0.21M | 0.63M | 3.00M | 3.00M | 3.00M | 3.00M | 3.00M | 3.00M | 3.87M | 3.87M | 6.68M | 6.68M | ||||||||||||
| Intangibles | 3.97M | 3.87M | 3.77M | 3.67M | 8.57M | 8.33M | 8.09M | 7.85M | 7.61M | 7.37M | 7.13M | 6.89M | 16.65M | ||||||||||||||||
| Goodwill & Intangibles | 3.97M | 3.87M | 3.77M | 3.67M | 8.57M | 8.33M | 8.09M | 7.85M | 7.61M | 7.37M | 7.13M | 6.89M | 16.65M | ||||||||||||||||
| Other Non-Current Assets | 1.13M | 0.89M | 0.60M | 0.58M | 0.59M | 0.53M | 1.45M | 1.25M | 1.51M | 1.32M | 0.85M | 0.89M | 6.16M | 3.18M | 3.78M | 3.74M | 3.86M | 2.72M | 2.66M | 3.12M | |||||||||
| Non-Current Assets | 2.96M | 2.73M | 2.55M | 2.39M | 2.49M | 2.57M | 5.45M | 9.06M | 9.36M | 8.55M | 14.26M | 19.18M | 20.29M | 19.98M | 20.57M | 32.86M | 39.38M | 43.91M | 49.15M | 60.08M | |||||||||
| Assets | 178.91M | 181.48M | 252.83M | 236.47M | 227.86M | 211.21M | 188.93M | 268.33M | 265.49M | 349.28M | 376.84M | 376.30M | 376.99M | 500.75M | 494.99M | 534.56M | 562.16M | 581.14M | 611.14M | 505.50M | |||||||||
| Liabilities | |||||||||||||||||||||||||||||
| Current Liabilities | |||||||||||||||||||||||||||||
| Accounts Payables | 8.68M | 10.81M | 8.94M | 10.18M | 9.91M | 9.05M | 9.46M | 15.35M | 23.69M | 36.57M | 43.53M | 54.54M | 55.37M | 76.38M | 78.64M | 103.50M | 101.53M | 110.85M | 123.73M | 158.09M | |||||||||
| Payables | 8.68M | 10.81M | 8.94M | 10.18M | 9.91M | 9.05M | 9.46M | 15.35M | 23.69M | 36.57M | 43.53M | 54.54M | 55.37M | 76.38M | 78.64M | 103.50M | 101.53M | 110.85M | 123.73M | 158.09M | |||||||||
| Other Accumulated Expenses | |||||||||||||||||||||||||||||
| Total Current Liabilities | 11.48M | 12.61M | 11.72M | 14.27M | 15.43M | 13.26M | 14.77M | 23.25M | 36.94M | 42.53M | 51.57M | 65.87M | 80.61M | 86.31M | 90.25M | 117.05M | 135.70M | 143.51M | 175.75M | 227.11M | |||||||||
| Non-Current Liabilities | |||||||||||||||||||||||||||||
| Non-Current Debt | 19.18M | 19.26M | 19.36M | 19.43M | 24.52M | 24.61M | 29.71M | 29.82M | 29.93M | 71.58M | 71.71M | 71.85M | 71.98M | 72.13M | 72.28M | 72.44M | 72.60M | 72.76M | 72.94M | ||||||||||
| Preferred Stock Liabilities | |||||||||||||||||||||||||||||
| Other Non-Current Liabilities | 0.70M | 0.50M | 0.34M | 0.21M | 0.10M | 0.04M | 1.83M | 1.71M | 1.75M | 1.61M | 1.45M | 1.24M | 10.15M | 10.60M | 16.08M | 15.90M | 149.08M | ||||||||||||
| Total Non-Current Liabilities | 11.48M | 31.79M | 30.98M | 33.63M | 34.86M | 37.77M | 39.37M | 52.96M | 66.76M | 72.46M | 123.15M | 137.58M | 152.46M | 189.33M | 208.13M | 216.11M | 248.52M | 252.39M | |||||||||||
| Total Liabilities | 12.18M | 32.29M | 31.32M | 33.84M | 34.96M | 37.81M | 41.20M | 54.67M | 68.50M | 74.07M | 124.60M | 138.82M | 152.46M | 158.29M | 162.38M | 199.48M | 218.73M | 232.18M | 264.41M | 401.47M | |||||||||
| Shareholder's Equity | |||||||||||||||||||||||||||||
| Total Debt | 19.18M | 19.26M | 19.36M | 19.43M | 24.52M | 24.61M | 29.71M | 29.82M | 29.93M | 71.58M | 71.71M | 71.85M | 71.98M | 72.13M | 72.28M | 72.44M | 72.60M | 72.76M | 72.94M | ||||||||||
| Common Equity | 166.73M | 149.20M | 221.51M | 202.63M | 192.90M | 173.40M | 147.73M | 213.66M | 196.99M | 275.21M | 252.25M | 237.48M | 224.53M | 342.46M | 332.61M | 335.08M | 343.43M | 348.95M | 346.73M | 104.03M | |||||||||
| Liabilities and Shareholders Equity | 178.91M | 181.48M | 252.83M | 236.47M | 227.86M | 211.21M | 188.93M | 268.33M | 265.49M | 349.28M | 376.84M | 376.30M | 376.99M | 500.75M | 494.99M | 534.56M | 562.16M | 581.14M | 611.14M | 505.50M | |||||||||
| Retained Earnings | -46.67M | -66.91M | -72.70M | -95.16M | -108.76M | -132.18M | -163.61M | -202.75M | -244.66M | -280.39M | -313.68M | -337.10M | -360.21M | -385.33M | -405.67M | -418.26M | -426.63M | -433.60M | -452.15M | -1,120.48M |
Pull Tarsus Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=TARS&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "TARS", "statement": "BS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=TARS&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();